SAB BIOTHERAPEUTICS INC (SABS)

These stocks are moving in today's after hours session

Monday's after hours session: top gainers and losers

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update...

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...

SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024

SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08,...

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company...

SAB BIO Appoints Lucy To as Chief Financial Officer

SAB BIO Appoints Lucy To as Chief Financial Officer

SAB BIO Appoints Lucy To as Chief Financial Officer ...

SAb Biotherapeutics Rebrands as SAB BIO

SAb Biotherapeutics Rebrands as SAB BIO

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1...

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a...

SAB Biotherapeutics Announces Departure of Chief Financial Officer

SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a...

SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024

SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024.

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics...

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Announces Q1 2024 Financial Results...

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a...

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes ...

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA. ...

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical...

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results